Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 16;25(4):e202300633.
doi: 10.1002/cbic.202300633. Epub 2023 Dec 4.

Recent Advances in RNA-Targeted Cancer Therapy

Affiliations
Review

Recent Advances in RNA-Targeted Cancer Therapy

Miao Li et al. Chembiochem. .

Abstract

Ribonucleic acid (RNA) plays a pivotal role in gene regulation and protein biosynthesis. Interfering the physiological function of key RNAs to induce cell apoptosis holds great promise for cancer treatment. Many RNA-targeted anti-cancer strategies have emerged continuously. Among them, RNA interference (RNAi) has been recognized as a promising therapeutic modality for various disease treatments. Nevertheless, the primary obstacle in siRNA delivery-escaping the endosome and crossing the plasma membrane severely impedes its therapeutic potential. Thus far, a variety of nanosystems as well as carrier-free bioconjugation for siRNA delivery have been developed and employed to enhance the drug delivery and anti-tumor efficiency. Besides, the use of small molecules to target specific RNA structures and disrupt their function, along with the covalent modification of RNA, has also drawn tremendous attention recently owing to high therapeutic efficacy. In this review, we will provide an overview of recent progress in RNA-targeted cancer therapy including various siRNA delivery strategies, RNA-targeting small molecules, and newly emerged covalent RNA modification. Finally, challenges and future perspectives faced in this research field will be discussed.

Keywords: RNA interference; gene therapy; ribonucleic acid; siRNA delivery; small molecule probe.

PubMed Disclaimer

References

    1. R. L. Siegel, K. D. Miller, N. S. Wagle, A. Jemal, Ca-Cancer J. Clin. 2023, 73, 17-48.
    1. None
    1. M. Barraqué, A. Filippello, A. Brek, S. Baccot, J. Porcheron, G. Barabino, J. Visc. Surg. 2019, 156, 229-237;
    1. G. Jeswani, S. D. Paul, A. K. Jha, Curr. Drug Delivery 2018, 15, 21-36;
    1. J. Ding, Q. Mao, M. Zhao, Y. Gao, A. Wang, S. Ye, X. Wang, W. Xie, H. Shi, Nanoscale 2020, 12, 22963-22969.

Publication types

Substances

LinkOut - more resources